Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this episode, Stefan Zeuzem, MD, discusses exciting new data on viral hepatitis reported at the virtual EASL 2021, including new findings on treatment of HDV, treatment of HBV and HCV in children, linking patients to care, and new molecules being investigated for HBV cure.
Stefan Zeuzem, MD
Professor of Medicine
Chief, Department of Medicine I
JW Goethe University Hospital
Anna Christina L. dela Cruz, MD, and Clinical Care Options (CCO): Treating for hepatitis B despite laboratory values in the gray zone
Dr. Geoffrey Dusheiko, in conversation with Mark, who was diagnosed with hepatitis B after receiving immunomodulatory treatment for rheumatoid arthritis from Clinical Care Options (CCO)
From Clinical Care Options (CCO): Dr. Oluwaseun Falade-Nwulia and Dr. Joseph K. Lim on HCV disparities/barriers in Black, Hispanic, Asian, American Indian, Alaska Native persons
Robert Gish on cure strategies at EASL 2021: si RNAs, JNJ-3989, AB-729, GSK3228836, VIR-3434, c-PAMs or capsid inhibitors, AB-836, and more from Clinical Care Options (CCO)